A RAPID, SENSITIVE AND VALIDATED ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY AND TANDEM MASS SPECTROMETRY METHOD FOR DETERMINATION OF PAROMOMYCIN IN MICE PLASMA: APPLICATION TO PHARMACOKINETIC STUDY
DOI:
https://doi.org/10.22159/ijpps.2017v9i5.11024.Keywords:
Paromomycin, Quantification, Pharmacokinetics, UPLC-MSMSAbstract
Objective: To develop and validate simple, sensitive, accurate and selective UPLC-MS/MS method for quantification of paromomycin (PARO) in mice plasma.
Methods: Precipitation method was used for the extraction of plasma samples, an aliquot of 25 µl plasma samples was extracted using 10% perchloric acid in water. Chromatographic separation was performed using waters acquity ultra-performance liquid chromatography (UPLC) columns, BEH HILIC (50 mm× 2.1 mm, 1.7 µm) by a gradient mixture of acetonitrile and water (both containing 0.005% v/v trifluro acetic acid) as a mobile phase at the flow rate of 0.2 ml/min. The analyte was protonated in the positive electrospray ionization (ESI) interface and detected in multiple reactions monitoring (MRM) modes using the transition m/z 308.60-455.30.
Results: The method had a short chromatographic run time of 3 min. Calibration curves were linear over wide ranges of 50.51-5019.22 ng/ml. The between and within-batch precision and accuracy of the method was determined by using 4 quality control samples, the highest % CV observed was 11.06. The mean recovery values are 78.17, 101.17 and 92.58 at low, medium and high-quality control levels; respectively.
Conclusion: It was concluded that the developed and validated UPLC-MS/MS method was rapid, sensitive, accurate, precise, linear, and specific. Therefore, this method can be used for quantification of PARO in mice plasma with various advantages over the reported methods.
Downloads
References
S Sunder. Drug resistance in Indian visceral leishmaniasis. Tropical Medicines and International Health; 2001. p. 849-54.
HC Maltezou. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol 2010;1-8. http://dx.doi.org/10.1155/ 2010/617521.
Lt Col, VK Agarwal, Brig Z Singh. Miltefosine: the first oral drug for treatment of visceral leishmaniasis. Drug Update 2005;62:1.
Karin Seifert, Simon L Croft. In vitro and in vivo interaction between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006;50:73-9.
Guerin PJ, P Olliaro, S Sundar, M Boelaert, SL Croft, P Desjeux, et al. Bryceson, visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2:494-501.
Alvar J, C Canavate, B Gutierrez-Solar, M Jimenez, F Laguna, R Lopez-Velez, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 y, 1997. Clin Microbiol Rev 1997;10:298-319.
Desjeux P. Leishmaniasis. Nat Rev Microbiol 2004;2:692.
Croft SL, GH Coombs. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003;19:502-8.
Sundar S, DK More, MK Singh, VP Singh, S Sharma, A Makharia, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: a report from the centre of the Indian epidemic. Clin Infect Dis 2000;31:1104-7.
White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 1999;41:301-8.
Dionex. Analysis of paromomycin by HPAE-IPAD; 2007.
Y Liu, S Hou. Development and validation of liquid chromatography method for analysis of paromomycin sulfate and its impurities. J Anal Bioanal Tech 2010;1:1-4.
S Sundar, TK Jha, CP Thakur, PK Sinha, SK BhattacDe Francia, SA D'Avolio, et al. Injectable paromomycin for visceral leishmaniasis. The New Eng J of Medi 2007;356:2571-81.
J Lu, M Cwik, T Kanyok. Determination of paromomycin in human plasma and urine by reversed high-performance liquid chromatography using 2,4-dinitroflurobenzene derivatization. J Chrom B: Biomed Appl 1997;695:329-35.
Published
How to Cite
Issue
Section
